Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCCNASDAQ:ENLVOTCMKTS:MATNNASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$0.34+1.0%$2.42$0.25▼$39.84$7.65M0.24399,510 shs1.29 million shsENLVEnlivex Therapeutics$1.09+4.3%$0.98$0.81▼$1.76$25.78M0.74127,719 shs139,267 shsMATNMateon Therapeutics$0.05+6.9%$0.06$0.13▼$0.38$4.20M1.33338,444 shs47,775 shsOVIDOvid Therapeutics$0.31+4.9%$0.30$0.24▼$1.47$22.07M0.08416,079 shs489,820 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals+1.01%-17.28%-78.29%-93.34%-98.58%ENLVEnlivex Therapeutics+4.31%+20.44%+11.28%+4.31%-15.50%MATNMateon Therapeutics0.00%-22.70%-23.64%-18.88%+27.30%OVIDOvid Therapeutics+4.90%+10.78%+8.65%-26.98%-60.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals0.181 of 5 stars0.03.00.00.00.01.70.0ENLVEnlivex Therapeutics2.6214 of 5 stars3.75.00.00.00.60.80.6MATNMateon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOVIDOvid Therapeutics4.514 of 5 stars3.63.00.04.63.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AENLVEnlivex Therapeutics 3.33Buy$10.00817.43% UpsideMATNMateon Therapeutics 0.00N/AN/AN/AOVIDOvid Therapeutics 3.20Buy$3.13906.77% UpsideCurrent Analyst Ratings BreakdownLatest MATN, CYCC, OVID, and ENLV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.504/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/21/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.004/3/2025ENLVEnlivex TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.00 ➝ $13.003/24/2025ENLVEnlivex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.00 ➝ $7.003/24/2025OVIDOvid TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$40K191.33N/AN/A($3.93) per share-0.09ENLVEnlivex TherapeuticsN/AN/AN/AN/A$1.00 per shareN/AMATNMateon TherapeuticsN/AN/AN/AN/A$0.20 per shareN/AOVIDOvid Therapeutics$570K38.72N/AN/A$0.96 per share0.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$11.21M-$56.00N/A∞N/A-18,150.00%-3,648.09%-155.99%6/24/2025 (Estimated)ENLVEnlivex Therapeutics-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)MATNMateon Therapeutics-$6.64MN/A0.00N/AN/AN/A-64.66%-42.92%N/AOVIDOvid Therapeutics-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)Latest MATN, CYCC, OVID, and ENLV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/24/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A5/30/2025Q1 2025ENLVEnlivex Therapeutics-$0.16-$0.15+$0.01-$0.15N/AN/A5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/31/2025Q4 2024ENLVEnlivex Therapeutics-$0.16-$0.23-$0.07-$0.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel PharmaceuticalsN/AN/AN/AN/AN/AENLVEnlivex TherapeuticsN/AN/AN/AN/AN/AMATNMateon TherapeuticsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ALatest MATN, CYCC, OVID, and ENLV DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A5.605.60ENLVEnlivex TherapeuticsN/A7.207.20MATNMateon TherapeuticsN/A0.170.17OVIDOvid Therapeutics0.224.934.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%ENLVEnlivex Therapeutics1.02%MATNMateon Therapeutics0.07%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals96.90%ENLVEnlivex Therapeutics12.28%MATNMateon Therapeutics39.22%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals1422.45 million696,000OptionableENLVEnlivex Therapeutics7023.65 million20.75 millionOptionableMATNMateon Therapeutics1390.24 millionN/ANot OptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableMATN, CYCC, OVID, and ENLV HeadlinesRecent News About These CompaniesAre These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?June 20 at 4:33 PM | msn.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Recommendation of "Buy" by BrokeragesJune 11, 2025 | americanbankingnews.comOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025June 5, 2025 | taiwannews.com.twOvid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander RotenbergJune 5, 2025 | quiverquant.comOvid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comPhoreMost makes key appointments to Board to advance development of next-generation degrader therapeuticsMay 8, 2025 | cambridgenetwork.co.ukOvid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comBiotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA CutsApril 10, 2025 | biospace.comOvid's Main Street Business Owners Are Speaking Out About Recovery Process After January FireApril 5, 2025 | weny.comOvid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 2, 2025 | markets.businessinsider.comNozzolio and NextEra to visit Ovid for donation event after Main Street fireApril 2, 2025 | fingerlakes1.comOvid Therapeutics price target lowered to $2 from $3 at H.C. WainwrightMarch 25, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $4 from $5 at BTIGMarch 25, 2025 | markets.businessinsider.comOvid man arrested for failing to register as sex offenderMarch 21, 2025 | fingerlakes1.comOvid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues LagMarch 12, 2025 | finance.yahoo.comWilliam Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)March 12, 2025 | markets.businessinsider.comOvid Therapeutics price target lowered to $3 from $4 at WedbushMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksGovernment Mandate Sends eVTOL Stocks FlyingBy Jeffrey Neal Johnson | June 10, 2025View Government Mandate Sends eVTOL Stocks FlyingGitLab: Buy It Low While You Still Can—Higher Prices Are ComingBy Thomas Hughes | June 11, 2025View GitLab: Buy It Low While You Still Can—Higher Prices Are ComingThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International MarketsMATN, CYCC, OVID, and ENLV Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$0.34 +0.00 (+1.01%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.34 +0.00 (+0.32%) As of 06/20/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Enlivex Therapeutics NASDAQ:ENLV$1.09 +0.05 (+4.31%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.10 +0.00 (+0.46%) As of 06/20/2025 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.Mateon Therapeutics OTCMKTS:MATN$0.05 +0.00 (+6.89%) As of 06/20/2025Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.Ovid Therapeutics NASDAQ:OVID$0.31 +0.01 (+4.90%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.31 +0.00 (+0.19%) As of 06/20/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
